Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP 938 versus EYLEA HD in neovascular age-related macular degeneration
2025-523500-72-00Phase 3Authorised
- Sponsor
- Amgen
- Start
- Aug 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of 9MW0813 and aflibercept in exudative macular degeneration (2 arms), sponsored by Amgen. Primary endpoint: Change from baseline in best corrected visual acuity. Planned start Aug 2026; status: authorised.
02
Drugs
9MW0813aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2025-523500-72-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523500-72-00.